Skip to main content
ACTU
NASDAQ Life Sciences

Director and 10% Owner Sells $1.62M in Actuate Therapeutics Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$6.73
Mkt Cap
$156.428M
52W Low
$5.47
52W High
$11.99
52W Position info
23% above low
Off High info
44% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ACTU sits 23% above its 52-week low of $5.47.

Summary

A director and 10% owner of Actuate Therapeutics, Todd S. Thomson, through Kairos Venture Partners II, L.P., sold $1.62 million worth of common stock in an open market transaction, representing over 1% of the company's market capitalization.


Key Events · Ownership and Investor Activity · ACTU

  • Significant Insider Sale

    Todd S. Thomson, a Director and 10% Owner, through Kairos Venture Partners II, L.P., disposed of 280,000 shares of common stock for a total value of $1,624,000 at a price of $5.80 per share.

  • Substantial Portion of Market Cap

    The transaction value of $1,624,000 represents a notable portion of Actuate Therapeutics' market capitalization, indicating a significant reduction in the insider's stake.

  • Material Reduction in Holdings

    The sale reduced Kairos Venture Partners II, L.P.'s direct holdings by approximately 23.6%, suggesting a material decrease in their position.


Analysis · ACTU · Life Sciences

The sale of $1.62 million in Actuate Therapeutics stock by a director and 10% owner, Todd S. Thomson (via Kairos Venture Partners II, L.P.), is a significant event given it represents over 1% of the company's market capitalization. While 10% owners often sell for portfolio rebalancing, the involvement of a director and the substantial size of the transaction (over 20% of their direct holdings) could signal a reduction in conviction or a need for liquidity. Investors should monitor future insider activity and company developments closely.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1410 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACTU was trading at $6.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $156.4M. The 52-week trading range was $5.47 to $11.99. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACTU - Latest Insights

ACTU
Oct 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3351
Real-time Price: $0.3477 info
Change: +$0.0126 (+4%) info
Market Cap: $17.985M info
ACTU
Oct 28, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3833
Real-time Price: $0.3477 info
Change: -$0.0356 (-9%) info
Market Cap: $17.985M info
ACTU
Oct 28, 2026, 8:00 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.370
Real-time Price: $0.3477 info
Change: -$0.0223 (-6%) info
Market Cap: $17.985M info
ACTU
Oct 27, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.4279
Real-time Price: $0.3477 info
Change: -$0.0802 (-19%) info
Market Cap: $17.985M info
ACTU
Oct 19, 2026, 8:00 AM EDT
Filing Type: S-1/A
Importance Score:
9
Price at Filing: $0.5805
Real-time Price: $0.3477 info
Change: -$0.2328 (-40%) info
Market Cap: $17.985M info